comparemela.com

Latest Breaking News On - Lilly mounjaro zepbound - Page 1 : comparemela.com

SA Asks: Who will launch the next big weight-loss drug? (NYSE:LLY)

Could Eli Lilly (LLY) and Novo Nordisk (NVO) soon face competition in the weight-loss drug market? Seeking Alpha analysts weigh in on who they think will launch the next big drug.

Lilly mounjaro zepboundNovo ozempic wegovyStephen ayersNovo nordiskEli lillyTerry chrisomalisZealand pharma boehringer ingelheimEdmund inghamEli lilly zepboundBoehringer ingelheimViking therapeuticsStructure therapeuticsSeeking alpha

3 Monster Stocks in the Making You Can Buy Right Now

These stocks might not be small for too much longer.

United statesDavid jagielski altimmuneLilly mounjaro zepboundNovo nordisk ozempic wegovyNovo nordiskEli lillyCalifornia redwood national parkGoldman sachsRedwood national parkMotley foolAxsome therapeuticsViking therapeuticsWhile novo nordiskJunior bakinyAxsome therapeuticMotley fool stock advisor

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.

Novo nordisk ozempic wegovyEli lillyLilly mounjaro zepboundAlbert bourlaDave dentonNovo nordisk ozempicNovo nordiskWall street

Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?

Real-world data showed some real-world advantages for Ozempic's top rival.

Lilly mounjaro zepboundTruveta researchNovo nordiskEli lilly

vimarsana © 2020. All Rights Reserved.